A Phase 4 interventional study of Mexidol in Ischemic Stroke, Acute, sponsored by Pharmasoft. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Pharmasoft · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Ischemic Stroke with a site in Russian Federation — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Russian Federation.
Among the 28 studies in Ischemic Stroke with a site in Russian Federation, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 4, and was the 23rd registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →6 of the 28 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:
Neurotechnika · Sites in Russian Federation
Ages 18–80
Skolkovo Institute of Science and Technology · Sites in Russian Federation
Ages 35–70 · Healthy volunteers
POLYSAN Scientific & Technological Pharmaceutical Company · Sites in Russian Federation
Ages 18+
POLYSAN Scientific & Technological Pharmaceutical Company · Sites in Russian Federation
Ages 18+
Mikhail Zykov · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 120 across the 19 interventional studies, 500 across the 9 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
Pharmasoft is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Pharmasoft has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Ischemic Stroke with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure
Modern neurorehabilitation is a set of basic and adjuvant treatment methods that provide a modulating effect on the neurorestoration process. The range of basic rehabilitation practices includes kinesiotherapy, occupational therapy, speech therapy, and neuropsychology. Adjuvant methods include physiotherapeutic and medicinal methods. For this study, the investigators chose MEXIDOL® as an adjuvant metabolic medicine, which has the ability to modulate receptor complexes of brain membranes, in particular benzodiazepine, GABA, acetylcholine, enhancing their ability to bind to specific ligands. This pharmacodynamic feature of the drug can have a positive effect on the psycho-emotional state of patients, which in turn will increase motivation and, consequently, the success of the rehabilitation process
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mexidol IV 500 mg for 10 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 8 weeks; and standard treatment
Drug: Mexidol
Standard treatment: basic practices of kinesitherapy, occupational therapy, speech therapy, clinical psychology, supplemented by adjuvant procedures of electrotherapy and rehabilitation environment therapy. The patient's rehabilitation load was at least 3 hours a day for 12 days
Neurocytoprotector
Also known as: Ethylmethylhydroxypyridine Succinate
Аssessment of Attentiveness and Performance
Schulte test \[work efficiency\]. Test methodology: the subject is successively shown 5 tables (5x5), in the cells of which numbers (from 1 to 25) are randomly located. It is required to show and name all the numbers in ascending order (from 1 to 25). The time spent on each table separately is recorded. Depending on the objectives, the excess of the standard (40-50 sec) time spent on each table and the dynamics of time indicators, or the average or total result of the examination for all five tables, are analyzed \[test time: min value 30.0 sec, max value N/A; higher scores mean a worse outcome\].
Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10) and at the end of the course of therapy (Day 66).
Dynamics of Cognitive Status
The Montreal Cognitive Assessment (MoCA test) \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]
Time frame: Assessed at screening (Day 0), at the end of the parenteral therapy phase (Day 10) and at the end of the course of therapy (Day 66); Day 66 reported
Severity of Depression
The Beck Depression Inventory (BDI scale) \[64 point scale: min value 0, max value 63, higher scores mean a worse outcome\]
Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Reduction in Anxiety
The Hospital Anxiety and Depression Scale (HADS) \[22 point scale: min value 0, max value 21, higher scores mean a worse outcome\]
Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Severity of Post Intensive Care Syndrome
The Post Intensive Care Syndrome (PICS) score \[21 point scale: min value 0, max value 10 with 0,5 point scale division, higher scores mean a worse outcome\]
Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Dynamics of Level of Mobility
The Rivermead index \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]
Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Dynamics of the Level of Life
The Rehabilitation Routing Scale (RRS) \[7 point scale: min value 0, max value 6, higher scores mean a worse outcome\]
Time frame: Assessed at screening (Day 0), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Severity and Dynamics of Muscle Strength
The Muscle Strength Quantitative Rating (MRC) Scale \[6 point scale: min value 0, max value 5, higher scores mean a better outcome\]
Time frame: Assessed before starting therapy (Day 1), at the end of the parenteral therapy phase (Day 10), in the middle of the oral therapy phase (Day 38) and at the end of the course of therapy (Day 66); Day 66 reported
Systolic Cerebral Blood Flow Velocity (Vs) Using Transcranial Doppler (TCD) at Key Time Points
Systolic cerebral blood flow velocity (Vs) was measured in сm/sec using transcranial Doppler ultrasonography (TCD). Measurements were taken for each participant at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[Normal values: min 35 сm/sec, max 95 сm/sec\]
Time frame: The TCDG parameters registrated before infusion, at the start of the infusion, at the start of the Schulte test, at the end of the Schulte test, at the end of the infusion.
Overshoot Coefficient (OC) of Systolic Cerebral Blood Flow Velocity (TCD) at Key Time Points
The Overshoot Coefficient (OC) is a ratio reflecting the change in systolic cerebral blood flow velocity before and after specific stimuli. It was calculated based on transcranial Doppler measurements at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[It's calculated by the formula OC=(Vo-Vs)/Vs, the norm is not less than 1.12\]
Time frame: The TCDG parameters registrated before infusion, at the start of the infusion, at the start of the Schulte test, at the end of the Schulte test, at the end of the infusion.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Registration of adverse events related to Mexidol and significant differences in vital signs between groups
Time frame: Throughout the study [From Day 1 up to Day 66]
| Milestone | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 30 |
| Not completed | 0 | 0 |
Schulte test \[work efficiency\]. Test methodology: the subject is successively shown 5 tables (5x5), in the cells of which numbers (from 1 to 25) are randomly located. It is required to show and name all the numbers in ascending order (from 1 to 25). The time spent on each table separately is recorded. Depending on the objectives, the excess of the standard (40-50 sec) time spent on each table and the dynamics of time indicators, or the average or total result of the examination for all five tables, are analyzed \[test time: min value 30.0 sec, max value N/A; higher scores mean a worse outcome\].
| seconds | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Day 1 | 94.9 (69.35 to 114.95) | 71.2 (65.15 to 87.9) |
| Day 10 | 75 (60.9 to 95.7) | 68.15 (62.15 to 88.65) |
| Day 66 | 71.7 (56.65 to 102.3) | 63 (55.73 to 82.95) |
The Montreal Cognitive Assessment (MoCA test) \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Dynamics of Cognitive Status | 23.8 ± 2.6 | 22.9 ± 3.0 |
The Beck Depression Inventory (BDI scale) \[64 point scale: min value 0, max value 63, higher scores mean a worse outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Severity of Depression | 7.5 ± 4.5 | 11.4 ± 5.6 |
The Hospital Anxiety and Depression Scale (HADS) \[22 point scale: min value 0, max value 21, higher scores mean a worse outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Reduction in Anxiety | 2.6 ± 2.4 | 4.4 ± 2.4 |
The Post Intensive Care Syndrome (PICS) score \[21 point scale: min value 0, max value 10 with 0,5 point scale division, higher scores mean a worse outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Severity of Post Intensive Care Syndrome | 0.02 ± 0.09 | 0.3 ± 0.6 |
The Rivermead index \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Dynamics of Level of Mobility | 10.3 ± 2.8 | 8.0 ± 2.8 |
The Rehabilitation Routing Scale (RRS) \[7 point scale: min value 0, max value 6, higher scores mean a worse outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Dynamics of the Level of Life | 2.9 ± 0.7 | 3.3 ± 0.6 |
The Muscle Strength Quantitative Rating (MRC) Scale \[6 point scale: min value 0, max value 5, higher scores mean a better outcome\]
| score on a scale | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Severity and Dynamics of Muscle Strength | 3.3 ± 5.1 | 2.1 ± 2.2 |
Systolic cerebral blood flow velocity (Vs) was measured in сm/sec using transcranial Doppler ultrasonography (TCD). Measurements were taken for each participant at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[Normal values: min 35 сm/sec, max 95 сm/sec\]
| сm/sec | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Before infusion | 72.6 ± 18.41 | 80.03 ± 33.49 |
| Start of the infusion | 72.23 ± 17.68 | 80.8 ± 33.09 |
| Start of the Schulte test | 74.6 ± 18.73 | 83.57 ± 34.3 |
| End of the Schulte test | 76.83 ± 17.76 | 80.87 ± 31.98 |
| End of the infusion | 78.53 ± 17.78 | 83.57 ± 32.29 |
The Overshoot Coefficient (OC) is a ratio reflecting the change in systolic cerebral blood flow velocity before and after specific stimuli. It was calculated based on transcranial Doppler measurements at five key time points: (1) before the first Mexidol infusion ("Before infusion"), (2) at the start of the infusion, (3) at the start of the Schulte test, (4) at the end of the Schulte test, and (5) at the end of the infusion. \[It's calculated by the formula OC=(Vo-Vs)/Vs, the norm is not less than 1.12\]
| ratio | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Before infusion | 1.25 ± 0.05 | 1.27 ± 0.05 |
| Start of the infusion | 1.26 ± 0.04 | 1.27 ± 0.04 |
| Start of the Schulte test | 1.25 ± 0.05 | 1.27 ± 0.04 |
| End of the Schulte test | 1.26 ± 0.05 | 1.27 ± 0.04 |
| End of the infusion | 1.27 ± 0.05 | 1.28 ± 0.04 |
Registration of adverse events related to Mexidol and significant differences in vital signs between groups
| Adverse events | Main (Mexidol and Standard Treatment) | Control |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 0 | 0 |
Collected over Throughout the study [From Day 1 up to Day 66]. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main (Mexidol and Standard Treatment) | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Control | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Age, Categorical(Participants) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 6 | 31 |
| >=65 years | 5 | 24 | 29 |
| Age, Continuous(years) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| Mean | 63.9 ± 10.3 | 66.6 ± 9.4 | 65.3 ± 9.8 |
| Sex: Female, Male(Participants) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| Female | 13 | 17 | 30 |
| Male | 17 | 13 | 30 |
| Race and Ethnicity Not Collected(Participants) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| Russia | 30 | 30 | 60 |
| Cognitive status [MoCA](units on a scale) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| Mean | 19.1 ± 2.26 | 19.6 ± 1.83 | 19.35 ± 2.05 |
| The Rehabilitation Routing Scale (RRS)(units on a scale) | Main (Mexidol and Standard Treatment) | Control | Total |
|---|---|---|---|
| Mean | 3.9 ± 0.4 | 4.1 ± 0.5 | 4.0 ± 0.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2023 to primary completion in Sep 2023, 4 months.
Results were first posted in Apr 2025, 1 year 7 months after primary completion.
Of 85 phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emoxypine succinate
Pharmasoft